ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Biophytis

Biophytis (ALBPS)

0.2999
-0.0021
(-0.70%)
Closed February 05 10:30AM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
0.2999
Bid
0.2965
Ask
0.30
Volume
143,139
0.296 Day's Range 0.308
0.0021 52 Week Range 1.40
Market Cap
Previous Close
0.302
Open
0.296
Last Trade
1135
@
0.2999
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
97,799
Shares Outstanding
295,702,507
Dividend Yield
-
PE Ratio
-5.21
Earnings Per Share (EPS)
-0.06
Revenue
-
Net Profit
-17.03M

About Biophytis

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Headquarters
Paris, Paris, Fra
Founded
-
Biophytis is listed in the Biological Pds,ex Diagnstics sector of the Euronext with ticker ALBPS. The last closing price for Biophytis was 0.30 €. Over the last year, Biophytis shares have traded in a share price range of 0.0021 € to 1.40 €.

Biophytis currently has 295,702,507 shares outstanding. The market capitalization of Biophytis is 89.30 € million. Biophytis has a price to earnings ratio (PE ratio) of -5.21.

ALBPS Latest News

ADRs Close Lower; Fanhua Slips 16%

This article was automatically generated by MarketWatch using technology from Automated Insights. International stocks trading in New York closed lower Friday, as the S&P/BNY Mellon index of...

Biophytis Shares Drop 11% After Request for Meeting With FDA on Covid-19 Treatment

By Chris Wack Biophytis shares fell 11% to $2.40 after the company said it has filed for a pre-submission meeting request with the Food and Drug Administration to discuss filing for emergency use...

Biophytis to Restate Previously Issued Financial Statements

PARIS and CAMBRIDGE, Mass., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS) (the “Company” or “Biophytis”), a clinical-stage biotechnology company...

Biophytis Receives FDA IND Clearance for COVA, a Phase 2/3 Clinical Trial with Sarconeos (BIO101) for the Treatment of Patien...

PARIS and CAMBRIDGE, Mass., July 02, 2020 (GLOBE NEWSWIRE) -- Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company specialized in the development of drug...

Biophytis Announces Results of 2019 Annual General Meeting of Shareholders

All resolutions within the competence of the Ordinary General Meeting adoptedSecond notice to reconvene the Extraordinary General Meeting to be held in the coming weeks PARIS and CAMBRIDGE...

Biophytis Enters into a Collaboration with the French Muscular Dystrophy Association (AFM-Telethon)

Provides funding for additional preclinical experiments and for the MYODA preparations for the clinical study in Duchenne muscular dystrophy (DMD) PARIS and CAMBRIDGE, Mass., June 13, 2019...

Biophytis Expands Daniel Schneiderman’s Role to Group Chief Financial Officer

PARIS and CAMBRIDGE, Mass., June 07, 2019 (GLOBE NEWSWIRE) -- Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics for...

Biophytis Announces Publication of its 2018 Annual Report

Files 2018 Annual Report with the AMFProvides first quarter 2019 financial statementsEnters into intellectual property agreement with Stanislas Veillet PARIS and CAMBRIDGE, Mass., May 22, 2019...

Biophytis Files Registration Statement for Proposed Initial Public Offering in the United States

PARIS and CAMBRIDGE, Mass., May 22, 2019 (GLOBE NEWSWIRE) -- Biophytis (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics for...

Biophytis Reports Annual 2018 Financial Results and Provides Operational Update

Clinical execution and advancement of our SARA program, including initiation of the SARA-INT Phase 2b clinical trial for sarcopeniaLaunch of our MYODA program for Duchenne muscular dystrophy...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.00893.058419243990.2910.31850.29021022430.30107558DE
4-0.1211-28.76484560570.4210.460.252208560.29346423DE
120.00592.006802721090.2940.460.25977990.30035501DE
26-0.2001-40.020.50.840.25742200.3837005DE
520.29526280.851063830.00471.40.002156067980.00702884DE
156-0.1151-27.7349397590.4151.40.002154471530.02506527DE
2600.133980.66265060240.1662.730.002147301000.27505672DE

ALBPS - Frequently Asked Questions (FAQ)

What is the current Biophytis share price?
The current share price of Biophytis is 0.2999 €
How many Biophytis shares are in issue?
Biophytis has 295,702,507 shares in issue
What is the market cap of Biophytis?
The market capitalisation of Biophytis is EUR 89.3M
What is the 1 year trading range for Biophytis share price?
Biophytis has traded in the range of 0.0021 € to 1.40 € during the past year
What is the PE ratio of Biophytis?
The price to earnings ratio of Biophytis is -5.21
What is the reporting currency for Biophytis?
Biophytis reports financial results in EUR
What is the latest annual profit for Biophytis?
The latest annual profit of Biophytis is EUR -17.03M
What is the registered address of Biophytis?
The registered address for Biophytis is 14 AVENUE DE L’OPERA, PARIS, PARIS, 75001
What is the Biophytis website address?
The website address for Biophytis is www.biophytis.com
Which industry sector does Biophytis operate in?
Biophytis operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
MLCOTCoretech 5
0.044 €
(46.67%)
142.41k
ALNMGNetMedia Group
1.80 €
(28.57%)
22.76k
ALALOAcheterLouerFR
0.032 €
(24.03%)
1.9M
MHMMyHotelMatch
0.41 €
(17.48%)
29.36k
VLAValneva SE
3.09 €
(16.96%)
4.57M
BIODSBiosynex DS
0.0008 €
(-96.14%)
464.1k
MLUMGUmalis Group
1.32 €
(-38.32%)
1.53k
TUVDSBio UV Group DS
0.0327 €
(-34.60%)
1.19M
ALVIOValerio Therapeutics
0.0586 €
(-24.58%)
1.43M
ALTROTronic s Microsystems
4.10 €
(-23.36%)
40
ATOAtos SE
0.0021 €
(0.00%)
181.61M
BCPBanco Comercial Portugues SA
0.493 €
(-0.28%)
55.02M
ALMASMastrad
0.0268 €
(16.52%)
19.77M
ALTDTonner Drones
0.013 €
(10.17%)
14.47M
ALAGOEPango SA
0.278 €
(-12.58%)
11.3M

Discussion

View Full Feed
vlispxpert vlispxpert 4 minutes ago
HLF, should be big bopper next week imo
Chartmaster Chartmaster 4 minutes ago
Nice post! Rally continues! .0048 this week imo
RITE
Truth_is_a_tool Truth_is_a_tool 4 minutes ago
Uhm. You replied to yourself. Looks like you are telling yourself GFY 🤣🤣🤣
KBLB
chen1992 chen1992 4 minutes ago
All eyes on MARAD, they have until Feb 19 at the latest to make some type of announcement
TGLO
vlispxpert vlispxpert 4 minutes ago
JSPR long long, said it many times ;)
JSPR
JFBroderick JFBroderick 4 minutes ago
We were presented with clear expectations from the company. Regardless of the reasoning behind the wait, at this point, I believe the company should stay the course. Looking forward to our Friday update.
ASII
Skankhunt43 Skankhunt43 5 minutes ago
Go picket a casino then, Mr wonderful
PSRU
vlispxpert vlispxpert 5 minutes ago
JSPR, 3 weeks for 1st run, 3 months for 2nd...not for the impatient, but I think next leg incoming...jmho
JSPR
Penny_Layne Penny_Layne 5 minutes ago
Trip 6...Brand spanking new 52-week low
AXXA
GrandAdmiralThrawn GrandAdmiralThrawn 5 minutes ago
HADV cmon buddy, when you see the SS, you’ll like it way better than most.
HADV
Monksdream Monksdream 5 minutes ago
RDDT, new 52 week high
https://investorshub.advfn.com/uimage/uploads/2025/2/5/hxxwwIMG_5007.gif
RDDT
Skankhunt43 Skankhunt43 6 minutes ago
I don't see you donating to my account. Of course I'm going to think about myself; nobody else will.
PSRU
TheKid5 TheKid5 6 minutes ago
M2MMA heading your way
MRES
Invest-in-America Invest-in-America 6 minutes ago
BBAI: Their FLOAT ain't no 'beauty' --- the only thing holding this BACK today.
BBAI
RNsidersbuying RNsidersbuying 6 minutes ago
PDEX 33.48 and CNRD 11.80 - entered both with intent of holding into earnings at these prices. Keep em coming?
Lone Clone Lone Clone 6 minutes ago
Riverside Resources and Fortuna Mining Progress with Phase 2 Exploration Program After Positive Drill Results from Q4 2024 Cecilia Drill Program Sonora, Mexico

https://www.newsfilecorp.com/release/239658

February 05, 2025 8:00 AM EST | Source: Riverside Resources Inc.
primecomm primecomm 7 minutes ago
$GRLF READY TO BLOW====>>> .001++ COMING.
GRLF
Power of Emouna Power of Emouna 7 minutes ago
Yes hopefully! $PSRU
PSRU
ByingLastard ByingLastard 7 minutes ago
Look what Porky pig has been up to!   No time for us but Johnny on the spot for this "critical " issue!
FNMA
x993231 x993231 7 minutes ago
What I can not get over is that some think a few hundred K per year is high for someone with Yves experience,

Here is what Yves brings to the table M&A wise and length that it usually takes him to do the dead,

He had 2 jobs while taking over the CEO roll.

LWLG
Sodapop42 Sodapop42 7 minutes ago
Nissan is walking away from merger talks with Honda over control. Nissan wanted a joint holding company, Honda wanted to make Nissan a subsidiary. One has to wonder if Henry convinced Nissan that it was a better deal to merge with PHIL, than with Honda.👀👀👀👀👀
PHIL
jimr1717 jimr1717 7 minutes ago
A fresh Delisting Notification Zzzzzz
LGMK
Pro_v12001 Pro_v12001 8 minutes ago
Pit, its old. We get it.
LWLG
Tree Tree 8 minutes ago
You suck. LOL
stevhoff stevhoff 8 minutes ago
$LOCO Sardar Biglari ha owned 15% of the out for a while, building position over last couple years. Latest filing has some additional info not disclosed previously:
Item 4. Purpose of Transaction

The Reporting Person will seek to engage in a dialogue with the Issuer's Board o
LOCO